<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer</h1>

    <table>
      <tr><th>Ticker</th><td>CADL</td></tr>
      <tr><th>Float</th><td>41.1 M</td></tr>
      <tr><th>IO</th><td>38.98%</td></tr>
      <tr><th>MC</th><td>327 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Candel Therapeutics announced a $100 million royalty funding agreement with RTW to support the potential launch of its gene-therapy candidate Aglatimagene Besadenovec (CAN-2409) for localized prostate cancer. The agreement is described as royalty financing to support commercialization efforts for CAN-2409; specific financial terms, royalty rate, and timing details are not provided in the available text.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Provides $100 million in funding to support potential launch and commercialization of CAN-2409</li><li>Strategic partnership with RTW (royalty/healthcare-focused investor) to advance a late-stage oncology asset</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Final economics and royalty rate of the financing are not disclosed in the available information</li><li>Royalty financing could reduce future revenue retained by the company if CAN-2409 is commercialized</li></ul>
    </div>

    <div class="section">
      <a href="https://newsfilter.io/articles/candel-therapeutics-announces-100m-royalty-funding-agreement-with-rtw-to-support-the-potential-launc-2e1991d08cce00ed34a33433a8103dfd" target="_blank">Original Article</a>
    </div>

    <div class="small">CADL â€¢ TradersLink AI News</div>
  </div>
</body>
</html>